TG Therapeutics Inc. (TGTX)

6.84
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 6.84
Open 6.94
Day Low/High 6.78 / 6.96
52 Wk Low/High 3.32 / 12.90
Volume 679.58K
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 94.75M
Market Cap 620.65M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
TG Therapeutics, Inc. To Present At The 36th Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. To Present At The 36th Annual J.P. Morgan Healthcare Conference

Presentation Scheduled for Thursday, January 11, 2018 at 7:30am PT

Interesting TGTX Put And Call Options For August 2018

Interesting TGTX Put And Call Options For August 2018

Investors in TG Therapeutics Inc saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TG Therapeutics Stock Sees Short Interest Move 11.2% Lower

TG Therapeutics Stock Sees Short Interest Move 11.2% Lower

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 2,012,255 share decrease in total short interest for TG Therapeutics Inc , to 15,880,967, a decrease of 11.25% since 11/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TG Therapeutics, Inc. Recaps Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Recaps Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

Investor and Analyst Reception to be Held on Sunday December 10, 2017 at 8:00pm ET at the Ritz Carlton Atlanta (Downtown) with Presentations by Leading Clinical Investigators

TG Therapeutics Announces Initiation Of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial In Follicular Lymphoma

TG Therapeutics Announces Initiation Of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial In Follicular Lymphoma

TGR-1202 (umbralisib) selected as the PI3K Delta inhibitor to be used in this multiple arm comparison study

TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2017 Financial Results

TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2017 Financial Results

Investor Conference Call to be Held Today, Wednesday, November 8, 2017 at 8:30am ET

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2017 Financial Results And Business Update

Investor Conference Call to be held Wednesday, November 8, 2017 at 8:30am ET

TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

Investor and Analyst Reception to be Held on Sunday December 10, 2017 at 8:00pm ET at the Ritz Carlton Atlanta (Downtown) with Presentations by Leading Clinical Investigators

Commit To Buy TG Therapeutics At $5, Earn 21% Using Options

Commit To Buy TG Therapeutics At $5, Earn 21% Using Options

Investors eyeing a purchase of TG Therapeutics Inc shares, but tentative about paying the going market price of $8.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $5 strike, which has a bid at the time of this writing of $1.05.

TG Therapeutics Provides Update On FDA Meeting For GENUINE Phase 3 Trial

TG Therapeutics Provides Update On FDA Meeting For GENUINE Phase 3 Trial

Follow-up meeting with FDA expected before year end

TG Therapeutics Announces Completion Of Target Enrollment In The UNITY-CLL Phase 3 Trial

TG Therapeutics Announces Completion Of Target Enrollment In The UNITY-CLL Phase 3 Trial

Enrollment expected to continue until mid-October to allow patients already identified an opportunity to participate in the trial

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

TG Therapeutics, Inc. Provides Business Update And Reports Second Quarter 2017 Financial Results

TG Therapeutics, Inc. Provides Business Update And Reports Second Quarter 2017 Financial Results

Investor Conference Call to be Held Today, Wednesday, August 9, 2017 at 8:30am ET

TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2017 Financial Results And Business Update

Investor Conference Call to be held Wednesday, August 9, 2017 at 8:30am ET

Interesting TGTX Put And Call Options For September 15th

Interesting TGTX Put And Call Options For September 15th

Investors in TG Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Short Interest In TG Therapeutics Moves 16.6% Higher

Short Interest In TG Therapeutics Moves 16.6% Higher

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 2,433,158 share increase in total short interest for TG Therapeutics Inc , to 17,111,572, an increase of 16.58% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D- (Sell)